The Endocrinology and Nutrition Service of Macarena joins the European research network INNODIA

The Virgen Macarena University Hospital consolidates its position as a benchmark in type 1 diabetes research with the incorporation of its Endocrinology and Nutrition Service into INNODIA, the main European collaboration network in this field. 

This continental alliance institution, which brings together leading entities in the research and development of new therapies for type 1 diabetes, aims to accelerate the development of innovative therapies for the prevention and treatment of this disease. Integration into INNODIA reflects the Sevillian hospital's commitment to cutting-edge science and its ability to translate advances into clinical practice. 

This international recognition of the Endocrinology and Nutrition Service of the Virgen Macarena University Hospital comes backed by an outstanding research career. Recent achievements include obtaining the Río Hortega contract in 2024, a highly competitive research training contract for medical specialists linked to pioneering projects in type 1 diabetes, as well as leadership in population studies evaluating the impact of technologies such as flash glucose monitoring. 

In addition, this Service actively participates in international clinical trials, standing out as the world's largest recruiter in a study of immunomodulatory therapies in early phases and as the first European centre in another Phase II trial. Likewise, for its scientific development in this area, the research team led by María Asunción Martínez Brocca, head of the aforementioned Service, has recently been recognized as a group attached to the Institute of Biomedicine of Seville . 

Likewise, the work of this Service is complemented by initiatives such as the creation of a specific area for pre-symptomatic type 1 diabetes and strategic collaborations with institutions such as CABIMER and the Biobank of the Public Health Service of Andalusia. These partnerships reinforce the translational approach of their research, which seeks not only to improve patients' metabolic control, but also to explore future therapies aimed at preserving insulin production. 

The incorporation into INNODIA is a boost to the international projection of the Virgen Macarena University Hospital and opens new avenues of collaboration to advance the management of type 1 diabetes, benefiting both patients and the health system as a whole. 

Source: Andalusian Health Service